Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![year 2025 growth-GettyImages-2153623617]( "2025 Outlook For CGT: Focus On Non-Oncology Indications, In Vivo Gene Editing, And POC")
2025 Outlook For CGT: Focus On Non-Oncology Indications, In Vivo Gene Editing, And POC12/4/2024Leaders from Kiji Therapeutics, Precision Biosciences, and Orgenesis weigh in on what will likely accelerate the development of novel treatments, potentially revolutionizing patient care across a wider range of diseases and bringing the promise of personalized medicine closer to reality in 2025 and beyond.
-
![Medical healthcare autoimmune disease-GettyImages-1449402295]( "CD70 & Autoimmune Diseases")
CD70 & Autoimmune Diseases11/26/2024Allogene Therapeutics' Dr. Zachary Roberts shares the clinical-stage biotech's rationale behind selecting CD70 as a target for activated T cells in autoimmune diseases.
-
![23_12_CGPodcast_1280x720_Ep87]( "Neogene's Focus On Off-The-Shelf TCR Therapies")
Neogene's Focus On Off-The-Shelf TCR Therapies10/31/2024This recap of Episode 87 of Cell & Gene: The Podcast shares Neogene Therapeutics' Carsten Linnemann, Ph.D.'s take on why "off-the-shelf" will make t-cell receptor therapies more accessible to patients.
-
![Mesa_2024]( "Highlights From ARM's 2024 Meeting On The Mesa")
Highlights From ARM's 2024 Meeting On The Mesa10/25/2024ARM's 2024 Meeting on the Mesa has concluded. Here are a few brief highlights from this year's conference.
-
![rare diagnosis GettyImages-1368429047]( "Global Regulatory Challenges Of Rare Diseases")
Global Regulatory Challenges Of Rare Diseases9/26/2024ISCT's Chief Regulatory Officer, Dr. Bambi Grilley, shares insights from the 2024 Global Regulatory Summit.
-
![23_12_CGPodcast_1280x720_Ep81]( "Mammoth Biosciences On Epigenetic Editing")
Mammoth Biosciences On Epigenetic Editing8/29/2024In case you missed it, this is a summary of Cell & Gene: The Podcast Episode 81 featuring Mammoth Biosciences' Lucas Harrington.
-
![AML Acute myeloid leukemia-GettyImages-1337752576]( "Gamma-Delta T-Cell Therapy for AML")
Gamma-Delta T-Cell Therapy for AML8/29/2024William Ho, CEO at IN8bio, shares the company’s progress with gamma-delta T-cell-based immunotherapies and why they represent a groundbreaking approach in oncology, including treatment for Acute Myeloid Leukemia (AML).
-
![Regenerative medicine-GettyImages-821148970]( "The Role Of Stem Cell Biology, Machine Learning, And Laser Optics On Regenerative Medicine")
The Role Of Stem Cell Biology, Machine Learning, And Laser Optics On Regenerative Medicine8/16/2024Cellino Biotech's CEO, Nabiha Saklayen, Ph.D., explains how the company plans to make personalized regenerative medicines viable at large scale for the first time.
-
![Car T cells attacking cancer cells-GettyImages-1171781191]( "Umoja Biopharma's Potential for First In Vivo CAR T To Enter Clinic")
Umoja Biopharma's Potential for First In Vivo CAR T To Enter Clinic7/31/2024Umoja Biopharma's Dr. Andy Scharenberg and David Fontana discuss the company's expectations for UB-VV111 to potentially become the first in vivo CAR T cell therapy to enter the clinic in the U.S.
-
![GettyImages-1369753139-FDA]( "Breaking Down The FDA Draft Guidance, \"Rare Diseases: Considerations For The Development Of Drugs And Biological Products\"")
Breaking Down The FDA Draft Guidance, "Rare Diseases: Considerations For The Development Of Drugs And Biological Products"7/24/2024Raj Bandaru, Associate Director in Regulatory Affairs and U.S. Regulatory Affairs Lead at Accenture provides rich context on parts of the recent FDA Draft Guidance.
